Review



human nectin 4  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems human nectin 4
    Human Nectin 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/pmc12778052-253-5-7?v=R%26D+Systems
    Average 94 stars, based on 5 article reviews
    human nectin 4 - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    recombinant human nectin4 his protein  (ACROBiosystems)
    95
    ACROBiosystems recombinant human nectin4 his protein
    Recombinant Human Nectin4 His Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/pm41916034-58-0-4?v=ACROBiosystems
    Average 95 stars, based on 1 article reviews
    recombinant human nectin4 his protein - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    human nectin 4  (R&D Systems)
    94
    R&D Systems human nectin 4
    Human Nectin 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/pmc12778052-253-5-7?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    human nectin 4 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    recombinant nectin 4 protein  (R&D Systems)
    94
    R&D Systems recombinant nectin 4 protein
    ( A ) Representative images of CD155 (top) <t>and</t> <t>Nectin-4</t> (bottom) IHC staining with low and high intensity. Scale bar: 100 μm. ( B ) Dot plot showing the distribution of immune reactive scores (IRS; CD155, n = 69; Nectin-4, n = 68). ( C ) Stacked columns depicting the proportion of patients with CD155 and Nectin-4 expression according to intensity. ( D ) Kaplan-Meier analysis of overall survival of R0-resected patients with PDAC according to low or high CD155 (left) or Nectin-4 (right) expression. P values of log rank test are indicated. ( E ) Table and forest plot depicting survival hazard ratios (HR) with 95% CI of CD155 and Nectin-4 IRS in multivariate Cox proportional hazards regression analysis including both R0- and R1-resected patients, shown as a function of clinicopathological parameters. * P < 0.05; ** P < 0.01.
    Recombinant Nectin 4 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/pmc12892910-160-27-30?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    recombinant nectin 4 protein - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    nectin 4  (R&D Systems)
    94
    R&D Systems nectin 4
    ( A ) Representative images of CD155 (top) <t>and</t> <t>Nectin-4</t> (bottom) IHC staining with low and high intensity. Scale bar: 100 μm. ( B ) Dot plot showing the distribution of immune reactive scores (IRS; CD155, n = 69; Nectin-4, n = 68). ( C ) Stacked columns depicting the proportion of patients with CD155 and Nectin-4 expression according to intensity. ( D ) Kaplan-Meier analysis of overall survival of R0-resected patients with PDAC according to low or high CD155 (left) or Nectin-4 (right) expression. P values of log rank test are indicated. ( E ) Table and forest plot depicting survival hazard ratios (HR) with 95% CI of CD155 and Nectin-4 IRS in multivariate Cox proportional hazards regression analysis including both R0- and R1-resected patients, shown as a function of clinicopathological parameters. * P < 0.05; ** P < 0.01.
    Nectin 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/pmc12557367-443-26-27?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    nectin 4 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    nectin  (R&D Systems)
    93
    R&D Systems nectin
    ( A ) Representative images of CD155 (top) <t>and</t> <t>Nectin-4</t> (bottom) IHC staining with low and high intensity. Scale bar: 100 μm. ( B ) Dot plot showing the distribution of immune reactive scores (IRS; CD155, n = 69; Nectin-4, n = 68). ( C ) Stacked columns depicting the proportion of patients with CD155 and Nectin-4 expression according to intensity. ( D ) Kaplan-Meier analysis of overall survival of R0-resected patients with PDAC according to low or high CD155 (left) or Nectin-4 (right) expression. P values of log rank test are indicated. ( E ) Table and forest plot depicting survival hazard ratios (HR) with 95% CI of CD155 and Nectin-4 IRS in multivariate Cox proportional hazards regression analysis including both R0- and R1-resected patients, shown as a function of clinicopathological parameters. * P < 0.05; ** P < 0.01.
    Nectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/us12435107-395-31-33?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    nectin - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    spr against nectin 1  (R&D Systems)
    93
    R&D Systems spr against nectin 1
    ( A ) Representative images of CD155 (top) <t>and</t> <t>Nectin-4</t> (bottom) IHC staining with low and high intensity. Scale bar: 100 μm. ( B ) Dot plot showing the distribution of immune reactive scores (IRS; CD155, n = 69; Nectin-4, n = 68). ( C ) Stacked columns depicting the proportion of patients with CD155 and Nectin-4 expression according to intensity. ( D ) Kaplan-Meier analysis of overall survival of R0-resected patients with PDAC according to low or high CD155 (left) or Nectin-4 (right) expression. P values of log rank test are indicated. ( E ) Table and forest plot depicting survival hazard ratios (HR) with 95% CI of CD155 and Nectin-4 IRS in multivariate Cox proportional hazards regression analysis including both R0- and R1-resected patients, shown as a function of clinicopathological parameters. * P < 0.05; ** P < 0.01.
    Spr Against Nectin 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nectin/us12435107-395-9-13?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    spr against nectin 1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Representative images of CD155 (top) and Nectin-4 (bottom) IHC staining with low and high intensity. Scale bar: 100 μm. ( B ) Dot plot showing the distribution of immune reactive scores (IRS; CD155, n = 69; Nectin-4, n = 68). ( C ) Stacked columns depicting the proportion of patients with CD155 and Nectin-4 expression according to intensity. ( D ) Kaplan-Meier analysis of overall survival of R0-resected patients with PDAC according to low or high CD155 (left) or Nectin-4 (right) expression. P values of log rank test are indicated. ( E ) Table and forest plot depicting survival hazard ratios (HR) with 95% CI of CD155 and Nectin-4 IRS in multivariate Cox proportional hazards regression analysis including both R0- and R1-resected patients, shown as a function of clinicopathological parameters. * P < 0.05; ** P < 0.01.

    Journal: JCI Insight

    Article Title: Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer

    doi: 10.1172/jci.insight.194290

    Figure Lengend Snippet: ( A ) Representative images of CD155 (top) and Nectin-4 (bottom) IHC staining with low and high intensity. Scale bar: 100 μm. ( B ) Dot plot showing the distribution of immune reactive scores (IRS; CD155, n = 69; Nectin-4, n = 68). ( C ) Stacked columns depicting the proportion of patients with CD155 and Nectin-4 expression according to intensity. ( D ) Kaplan-Meier analysis of overall survival of R0-resected patients with PDAC according to low or high CD155 (left) or Nectin-4 (right) expression. P values of log rank test are indicated. ( E ) Table and forest plot depicting survival hazard ratios (HR) with 95% CI of CD155 and Nectin-4 IRS in multivariate Cox proportional hazards regression analysis including both R0- and R1-resected patients, shown as a function of clinicopathological parameters. * P < 0.05; ** P < 0.01.

    Article Snippet: One day prior seeding, 96-well plates (U-bottom, Greiner Bio-One) were coated overnight with 10 μg/mL anti-CD3 (BioLegend, RRID:AB_11146991), 10 μg/mL anti-CD28 (BioLegend, RRID:AB_11148949) together with 20 μg/mL recombinant Nectin-4 protein (R&D Systems).

    Techniques: Immunohistochemistry, Expressing

    ( A and B ) Percentage of T cells among all immune cells (left) and percentage of indicated T cell subsets among all T cells (right) in blood ( A ) and PDAC ( B ) for low and high Nectin-4 expression ( n = 68). ( C and D ) Percentage of TIGIT, CD226 and CD96 expression (from left to right) for indicated T cell subsets in blood ( C ) and PDAC ( D ) for low and high Nectin-4 expression. Each point represents data from 1 patient. Medians are shown as horizontal lines. Unpaired 2-tailed t tests with Holm-Šídák correction. * P < 0.05.

    Journal: JCI Insight

    Article Title: Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer

    doi: 10.1172/jci.insight.194290

    Figure Lengend Snippet: ( A and B ) Percentage of T cells among all immune cells (left) and percentage of indicated T cell subsets among all T cells (right) in blood ( A ) and PDAC ( B ) for low and high Nectin-4 expression ( n = 68). ( C and D ) Percentage of TIGIT, CD226 and CD96 expression (from left to right) for indicated T cell subsets in blood ( C ) and PDAC ( D ) for low and high Nectin-4 expression. Each point represents data from 1 patient. Medians are shown as horizontal lines. Unpaired 2-tailed t tests with Holm-Šídák correction. * P < 0.05.

    Article Snippet: One day prior seeding, 96-well plates (U-bottom, Greiner Bio-One) were coated overnight with 10 μg/mL anti-CD3 (BioLegend, RRID:AB_11146991), 10 μg/mL anti-CD28 (BioLegend, RRID:AB_11148949) together with 20 μg/mL recombinant Nectin-4 protein (R&D Systems).

    Techniques: Expressing

    ( A ) IFN-γ and TNF-α production by peripheral T cells from patients with PDAC after in vitro stimulation with anti-CD3 and anti-CD28 in the presence of plate-bound (pb, n = 8) or soluble (s, n = 4) Nectin-4. Each point represents data from 1 patient. Data are shown as mean ± SD. Unpaired 2-tailed t tests with Welch’s correction. * P < 0.05; ** P < 0.001; *** P < 0.001; **** P < 0.0001. ( B ) Representative expression level of PVRL4 by qPCR (bars indicate mean of technical duplicates). ( C ) Nectin-4 expression in PDAC PDOs by Western blot. ( D ) Dose response curves from PDAC PDOs treated with FOLFIRINOX, gemcitabine plus paclitaxel (Gem/Pac), or enfortumab vedotin. The relative viability in percentage at a given drug concentration of 2 independent biological replicates is shown. ( E ) Z scores generated from relative AUC from dose response curves from PDAC PDOs either treated with FOLFIRINOX, Gem/Pac, or enfortumab vedotin. ( F ) Representative images of 2 PDAC PDOs either treated with the standard regimen FOLFIRINOX, Gem/Pac, or enfortumab vedotin. PDOs were stained with caspase-3 dye profiling apoptosis (green) and imaged after 3 days. Scale bar: 50 μm.

    Journal: JCI Insight

    Article Title: Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer

    doi: 10.1172/jci.insight.194290

    Figure Lengend Snippet: ( A ) IFN-γ and TNF-α production by peripheral T cells from patients with PDAC after in vitro stimulation with anti-CD3 and anti-CD28 in the presence of plate-bound (pb, n = 8) or soluble (s, n = 4) Nectin-4. Each point represents data from 1 patient. Data are shown as mean ± SD. Unpaired 2-tailed t tests with Welch’s correction. * P < 0.05; ** P < 0.001; *** P < 0.001; **** P < 0.0001. ( B ) Representative expression level of PVRL4 by qPCR (bars indicate mean of technical duplicates). ( C ) Nectin-4 expression in PDAC PDOs by Western blot. ( D ) Dose response curves from PDAC PDOs treated with FOLFIRINOX, gemcitabine plus paclitaxel (Gem/Pac), or enfortumab vedotin. The relative viability in percentage at a given drug concentration of 2 independent biological replicates is shown. ( E ) Z scores generated from relative AUC from dose response curves from PDAC PDOs either treated with FOLFIRINOX, Gem/Pac, or enfortumab vedotin. ( F ) Representative images of 2 PDAC PDOs either treated with the standard regimen FOLFIRINOX, Gem/Pac, or enfortumab vedotin. PDOs were stained with caspase-3 dye profiling apoptosis (green) and imaged after 3 days. Scale bar: 50 μm.

    Article Snippet: One day prior seeding, 96-well plates (U-bottom, Greiner Bio-One) were coated overnight with 10 μg/mL anti-CD3 (BioLegend, RRID:AB_11146991), 10 μg/mL anti-CD28 (BioLegend, RRID:AB_11148949) together with 20 μg/mL recombinant Nectin-4 protein (R&D Systems).

    Techniques: In Vitro, Expressing, Western Blot, Concentration Assay, Generated, Staining